Skip to main content
SpringerLink
Log in

Drugs of abuse: management of intoxication and antidotes

  • Chapter
Molecular, Clinical and Environmental Toxicology

Part of the book series: Experientia Supplementum ((EXS,volume 100))

Abstract

Illicit drug intoxications are an increasing public health problem for which, in most cases, no antidotes are clinically available. The diagnosis and treatment of these intoxications requires a trained clinician with experience in recognizing the specific signs and symptoms of intoxications to individual drugs as well as polydrug intoxications, which are more the rule than the exception. To make the diagnosis, the clinical observation and a urine toxicology test are often enough. Evaluating the blood levels of drugs is frequently not practical because the tests can be expensive and results may be delayed and unavailable to guide the establishment of a, treatment plan. Other laboratory tests may be useful depending on the drug or drugs ingested and the presence of other medical complications. The treatment should be provided in a quiet, safe and reassuring environment. Vital signs should be closely monitored. Changes in blood pressure, respiratory frequency and temperature should be promptly treated, particularly respiratory depression (in cases of opiate intoxication) or hyperthermia (in cases of cocaine or amphetamine intoxication). Intravenous fluids should be administered as soon as possible. Other psychiatric and medical complication should receive appropriate symptomatic treatment. Research on immunotherapies, including vaccines, monoclonal and catalytic antibodies, seems to be a promising approach that may yield specific antidotes for drugs of abuse, helping to ameliorate the morbidity and mortality associated with illicit drug intoxications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Paulozzi LJ, Xi Y (2008) Recent changes in drug poisoning mortality in the United States by urban-rural status and by drug type. Pharmaco epidemiol Drug Saf 17: 997–1005

    Google Scholar 

  2. CDC (2007) Unintentional poisoning deaths — United States, 1999–2004. MMWR Morb Mortal Wkly Rep 56: 93–96

    Google Scholar 

  3. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ (2008) Patterns of abuse among unintentional pharmaceutical overdose fatalities. J Am Med Assoc 300: 2613–2620

    CAS  Google Scholar 

  4. CDC (2006) Toxicology testing and results for suicide victims — 13 states, 2004. MMWR Morb Mortal Wkly Rep 55: 1245–1248

    Google Scholar 

  5. Substance Abuse and Mental Health Services Administration, Office of Applied Studies (2008) Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits. DHHS Publication No. (SMA) 08-4339. Rockville, MD. DAWN Series D-30.

    Google Scholar 

  6. Paulozzi LJ, Budnitz DS, Xi Y (2006) Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 15: 618–627

    PubMed  Google Scholar 

  7. Paulozzi LJ, Annest JL (2007) US data show sharply rising drug-induced death rates. Inj Prev 13: 130–132.

    PubMed  Google Scholar 

  8. Snyder SH, Pert CB, Pasternak GW (1974) The opiate receptor. Ann Intern Med 81: 534–540

    CAS  PubMed  Google Scholar 

  9. Schuster CR, Smith BB, Jaffe JH (1971) Drug abuse in heroin users. An experimental study of self-administration of methadone codeine, and pentazocine. Arch Gen Psychiatry 24: 359–362

    CAS  PubMed  Google Scholar 

  10. Jasinski DR, Preston KL (1986) Comparison of intravenously administered methadone, morphine and heroin. Drug Alcohol Depend 17: 301–310

    CAS  PubMed  Google Scholar 

  11. Kuhar MJ (1978) Opiate receptors: Some anatomical and physiological aspects. Ann NY Acad Sci 311: 35–48

    CAS  PubMed  Google Scholar 

  12. Utecht MJ, Stone AF, McCarron MM (1993) Heroin body packers. J Emerg Med 11: 33–40

    CAS  PubMed  Google Scholar 

  13. Cullen W, Bury G., Langton D (2000) Experience of heroin overdose among drug users attending general practice. Br J Gen Pract 50: 546–549

    CAS  PubMed  Google Scholar 

  14. Tagliaro F, De BZ (1999) Heroin overdose is often the truer description. Addiction 94: 973–974

    CAS  PubMed  Google Scholar 

  15. Sporer KA (1999) Acute heroin overdose. Ann Intern Med 130: 584–590

    CAS  PubMed  Google Scholar 

  16. Darke S, Zador D (1996) Fatal heroin ‘overdose’: A review. Addiction 91: 1765–1772

    CAS  PubMed  Google Scholar 

  17. Duberstein JL, Kaufman DM (1971) A clinical study of an epidemic of heroin intoxication and heroin-induced pulmonary edema. Am J Med 51: 704–714

    CAS  PubMed  Google Scholar 

  18. Safwat AM, Daniel D (1983) Grand mal seizure after fentanyl administration. Anesthesiology 59: 78

    CAS  PubMed  Google Scholar 

  19. McCann B, Hunter R, McCann J (2002) Cocaine/heroin induced rhabdomyolysis and ventricular fibrillation. Emerg Med J 19: 264–265

    CAS  PubMed  Google Scholar 

  20. Cone EJ, Darwin WD (1992) Rapid assay of cocaine, opiates and metabolites by gas chromatography — mass spectrometry. J Chromatogr 580: 43–61

    CAS  PubMed  Google Scholar 

  21. Cone EJ, Caplan YH, Black DL, Robert T, Moser F (2008) Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol 32: 530–543

    CAS  PubMed  Google Scholar 

  22. Goldberger BA, Cone EJ, Grant TM, Caplan YH, Levine BS, Smialek JE (1994) Disposition of heroin and its metabolites in heroin-related deaths. J Anal Toxicol 18: 22–28

    CAS  PubMed  Google Scholar 

  23. Yang W, Barnes AJ, Ripple MG, Fowler DR, Cone EJ, Moolchan ET, Chung H, Huestis MA (2006) Simultaneous quantification of methamphetamine, cocaine, codeine, and metabolites in skin by positive chemical ionization gas chromatography—mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 833: 210–218

    CAS  PubMed  Google Scholar 

  24. Dixon P (2007) Managing acute heroin overdose. Emerg Nurse 15: 30–35

    PubMed  Google Scholar 

  25. Strang J (2002) Looking beyond death: Paying attention to other important consequences of heroin overdose. Addiction 97: 927–928

    PubMed  Google Scholar 

  26. Strang J, Kelleher M, Best D, Mayet S, Manning V (2006) Emergency naloxone for heroin overdose. BMJ 333: 614–615

    PubMed  Google Scholar 

  27. Wasiak J, Clavisi O (2002) Is subcutaneous or intramuscular naloxone as effective as intravenous naloxone in the treatment of life-threatening heroin overdose? Med J Aust 176: 495

    PubMed  Google Scholar 

  28. Maio RF, Gaukel B, Freeman B (1987) Intralingual naloxone injection for narcotic-induced respiratory depression. Ann Emerg Med 16: 572–573.

    CAS  PubMed  Google Scholar 

  29. Wanger K, Brough L, Macmillan I, Goulding J, MacPhail I, Christenson JM (1998) Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose. Acad Emerg Med 5: 293–299

    CAS  PubMed  Google Scholar 

  30. O’Brien CP, Greenstein R, Ternes J, Woody GE (1978) Clinical pharmacology of narcotic antagonists. Ann NY Acad Sci 311: 232–240

    PubMed  Google Scholar 

  31. Gal TJ (1989) Naloxone reversal of buprenorphine-induced respiratory depression. Clin Pharmacol Ther 45: 66–71

    CAS  PubMed  Google Scholar 

  32. Umans JG, Szeto HH (1985) Precipitated opiate abstinence in utero. Am J Obstet Gynecol 151: 441–444

    CAS  PubMed  Google Scholar 

  33. Zuspan FP, Gumpel JA, Mejia-Zelaya A, Madden J, Davis R (1975) Fetal stress from methadone withdrawal. Am J Obstet Gynecol 122: 43–46

    CAS  PubMed  Google Scholar 

  34. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A (2008) Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther Drug Monit 30: 490–496

    CAS  PubMed  Google Scholar 

  35. Steinberg AD, Karliner JS (1968) The clinical spectrum of heroin pulmonary edema. Arch Intern Med 122: 122–127

    CAS  PubMed  Google Scholar 

  36. Kim D, Irwin KS, Khoshnood K (2009) Expanded access to naloxone: Options for critical response to the epidemic of opioid overdose mortality. Am J Public Health 99: 402–407

    PubMed  Google Scholar 

  37. Brzozowski M, Shih RD, Bania TC, Hoffman RS (1993) Discharging heroin overdose patients after observation. Ann Emerg Med 22: 1638–1639

    CAS  PubMed  Google Scholar 

  38. Christenson J, Etherington J, Grafstein E, Innes G, Pennington S, Wanger K, Fernandes C, Spinelli JJ, Gao M (2000) Early discharge of patients with presumed opioid overdose: Development of a clinical prediction rule. Acad Emerg Med 7: 1110–1118

    CAS  PubMed  Google Scholar 

  39. Etherington J, Christenson J, Innes G, Grafstein E, Pennington S, Spinelli JJ, Gao M, Lahiffe B, Wanger K, Fernandes C (2000) Is early discharge safe after naloxone reversal of presumed opioid overdose? Can J Emerg Med 2: 156–162

    CAS  Google Scholar 

  40. Akbarzadeh A, Mehraby M, Zarbakhsh M, Farzaneh H (1999) Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem 30: 139–146

    CAS  PubMed  Google Scholar 

  41. Anton B, Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24: 3232–3240

    CAS  PubMed  Google Scholar 

  42. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252: 708–710

    CAS  PubMed  Google Scholar 

  43. Spector S, Berkowitz B, Flynn EJ, Peskar B (1973) Antibodies to morphine, barbiturates, and serotonin. Pharmacol Rev 25: 281–291

    CAS  PubMed  Google Scholar 

  44. Wainer BH, Fitch FW, Fried J, Rothberg RM (1973) A measurement of the specificities of antibodies to morphine-6-succinyl-BSA by competitive inhibition of 14C-morphine binding. J Immunol 110: 667–673

    CAS  PubMed  Google Scholar 

  45. Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1973) In vitro morphine antagonism by antibodies. Nature 241: 537–538

    CAS  PubMed  Google Scholar 

  46. Gay GR, Sheppard CW, Inaba DS, Newmeyer JA (1973) An old girl: flyin’ low, dyin’ slow, blinded by snow: Cocaine in perspective. Int J Addict 8: 1027–1042

    CAS  PubMed  Google Scholar 

  47. Siegel RK (1984) Changing patterns of cocaine use: Longitudinal observations, consequences, and treatment. NIDA Res Monogr 50: 92–110

    CAS  PubMed  Google Scholar 

  48. Siegel RK, ElSohly MA, Plowman T, Rury PM, Jones RT (1986) Cocaine in herbal tea. J Am Med Assoc 225: 40

    Google Scholar 

  49. Floren AE, Small JW (1993) Mate de coca equals cocaine. J Occup Med 35: 95–96

    CAS  PubMed  Google Scholar 

  50. Jenkins AJ, Llosa T, Montoya I, Cone EJ (1996) Identification and quantitation of alkaloids in coca tea. Forensic Sci Int 77: 179–189

    CAS  PubMed  Google Scholar 

  51. Jackson GF, Saady JJ, Poklis A (1991) Urinary excretion of benzoylecgonine following ingestion of Health Inca Tea. Forensic Sci Int 49: 57–64

    CAS  PubMed  Google Scholar 

  52. Rump AF, Theisohn M, Klaus W (1995) The pathophysiology of cocaine cardiotoxicity. Forensic Sci Int 71: 103–115

    CAS  PubMed  Google Scholar 

  53. Barnett G, Hawks R, Resnick R (1981) Cocaine pharmacokinetics in humans. J Ethnopharmacol 3: 353–366

    CAS  PubMed  Google Scholar 

  54. Leri F, Bruneau J, Stewart J (2003) Understanding polydrug use: Review of heroin and cocaine co-use. Addiction 98: 7–22

    PubMed  Google Scholar 

  55. Patel MB, Opreanu M, Shah AJ, Pandya K, Bhadula R, Abela GS, Thakur RK (2009) Cocaine and alcohol: A potential lethal duo. Am J Med 122: e5–e6

    Google Scholar 

  56. Renfroe CL, Messinger TA (1985) Street drug analysis: An eleven year perspective on illicit drug alteration. Semin Adolesc Med 1: 247–257

    CAS  PubMed  Google Scholar 

  57. June R, Aks SE, Keys N, Wahl M (2000) Medical outcome of cocaine bodystuffers. J Emerg Med 18: 221–224

    CAS  PubMed  Google Scholar 

  58. McCarron MM, Wood JD (1983) The cocaine ‘body packer’ syndrome. Diagnosis and treatment. J Am Med Assoc 250: 1417–1420

    CAS  Google Scholar 

  59. Mott SH, Packer RJ, Soldin SJ (1994) Neurologic manifestations of cocaine exposure in childhood. Pediatrics 93: 557–560

    CAS  PubMed  Google Scholar 

  60. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR (1992) Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emerg Med 21: 247–253

    CAS  PubMed  Google Scholar 

  61. Havlik DM, Nolte KB (2000) Fatal “crack” cocaine ingestion in an infant. Am J Forensic Med Pathol 21: 245–248

    CAS  PubMed  Google Scholar 

  62. Sherer MA (1988) Intravenous cocaine: Psychiatric effects, biological mechanisms. Biol Psychiatry 24: 865–885

    CAS  PubMed  Google Scholar 

  63. Bauwens JE, Boggs JM, Hartwell PS (1989) Fatal hyperthermia associated with cocaine use. West J Med 150: 210–212

    CAS  PubMed  Google Scholar 

  64. Callaway CW, Clark RF (1994) Hyperthermia in psychostimulant overdose. Ann Emerg Med 24: 68–76

    CAS  PubMed  Google Scholar 

  65. Siegel RK (1977) Cocaine: Recreational use and intoxication. NIDA Res Monogr 13: 119–136

    PubMed  Google Scholar 

  66. Zeiter JH, McHenry JG, McDermott ML (1990) Unilateral pharmacologic mydriasis secondary to crack cocaine. Am J Emerg Med 8: 568–569

    CAS  PubMed  Google Scholar 

  67. Daggett RB, Haghighi P, Terkeltaub RA (1990) Nasal cocaine abuse causing an aggressive midline intranasal and pharyngeal destructive process mimicking midline reticulosis and limited Wegener’s granulomatosis. J Rheumatol 17: 838–840

    CAS  PubMed  Google Scholar 

  68. Ribeiro M, Dunn J, Sesso R, Dias AC, Laranjeira R (2006) Causes of death among crack cocaine users. Rev Bras Psiquiatr 28: 196–202

    PubMed  Google Scholar 

  69. Blaho K, Logan B, Winbery S, Park L, Schwilke E (2000) Blood cocaine and metabolite concentrations, clinical findings, and outcome of patients presenting to an ED. Am J Emerg Med 18: 593–598

    CAS  PubMed  Google Scholar 

  70. Om A, Ellahham S, Ornato JP (1992) Reversibility of cocaine-induced cardiomyopathy. Am Heart J 124: 1639–1641

    CAS  PubMed  Google Scholar 

  71. Willens HJ, Chakko SC, Kessler KM (1994) Cardiovascular manifestations of cocaine abuse. A case of recurrent dilated cardiomyopathy. Chest 106: 594–600

    CAS  PubMed  Google Scholar 

  72. Lora-Tamayo C, Tena T, Rodriguez A (1994) Cocaine-related deaths. J Chromatogr A 674: 217–224

    CAS  PubMed  Google Scholar 

  73. Finkle BS, McCloskey KL (1977) The forensic toxicology of cocaine. NIDA Res Monogr 13: 153–192

    CAS  PubMed  Google Scholar 

  74. Malbrain ML, Wauters A, Demeyer I, Demedts P, Verbraeken H, Daelemans R, Neels H (1993) Drug smuggler’s delirium. BMJ 306: 1002

    CAS  PubMed  Google Scholar 

  75. Nnadi CU, Mimiko OA, McCurtis HL, Cadet JL (2005) Neuropsychiatric effects of cocaine use disorders. J Natl Med Assoc 97: 1504–1515

    PubMed  Google Scholar 

  76. Zagnoni PG, Albano C (2002) Psychostimulants and epilepsy. Epilepsia 43 Suppl 2: 28–31

    PubMed  Google Scholar 

  77. Pudiak CM, Bozarth MA (1994) Cocaine fatalities increased by restraint stress. Life Sci 55: L379–L382

    Google Scholar 

  78. Pascual-Leone A, Dhuna A, Altafullah I, Anderson DC (1990) Cocaine-induced seizures. Neurology 40: 404–407

    CAS  PubMed  Google Scholar 

  79. Kramer LD, Locke GE, Ogunyemi A, Nelson L (1990) Cocaine-related seizures in adults. Am J Drug Alcohol Abuse 16: 307–317

    CAS  PubMed  Google Scholar 

  80. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, Simon RP (1987) Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 83: 841–846

    CAS  PubMed  Google Scholar 

  81. Myers JA, Earnest MP (1984) Generalized seizures and cocaine abuse. Neurology 34: 675–676

    CAS  PubMed  Google Scholar 

  82. Peyriere H, Mauboussin JM (2000) Cocaine-induced acute cytologic hepatitis in HIV-infected patients with nonactive viral hepatitis. Ann Intern Med 132: 1010–1011

    CAS  PubMed  Google Scholar 

  83. Van der Woude FJ, Waldherr R (1999) Severe renal arterio-arteriolosclerosis after cocaine use. Nephrol Dial Transplant 14: 434–435

    PubMed  Google Scholar 

  84. Merigian KS, Roberts JR (1987) Cocaine intoxication: Hyperpyrexia, rhabdomyolysis and acute renal failure. J Toxicol Clin Toxicol 25: 135–148

    CAS  PubMed  Google Scholar 

  85. Menashe PI, Gottlieb JE (1988) Hyperthermia, rhabdomyolysis, and myoglobinuric renal failure after recreational use of cocaine. South Med J 81: 379–381

    CAS  PubMed  Google Scholar 

  86. Ahijado F, Garcia de V, Luno J (1990) Acute renal failure and rhabdomyolysis following cocaine abuse. Nephron 54: 268

    CAS  PubMed  Google Scholar 

  87. Enriquez R, Palacios FO, Gonzalez CM, Amoros FA, Cabezuelo JB, Hernandez F (1991) Skin vasculitis, hypokalemia and acute renal failure in rhabdomyolysis associated with cocaine. Nephron 59: 336–337

    CAS  PubMed  Google Scholar 

  88. Herzlich BC, Arsura EL, Pagala M, Grob D (1988) Rhabdomyolysis related to cocaine abuse. Ann Intern Med 109: 335–336

    CAS  PubMed  Google Scholar 

  89. Beerman R, Nunez D Jr, Wetli CV (1986) Radiographic evaluation of the cocaine smuggler. Gastrointest Radiol 11: 351–354

    CAS  PubMed  Google Scholar 

  90. Hoffman RS, Thompson T, Henry GC, Hatsukami DK, Pentel PR (1998) Variation in human plasma cholinesterase activity during low-dose cocaine administration. J Toxicol Clin Toxicol 36: 3–9

    CAS  PubMed  Google Scholar 

  91. Mattes CE, Lynch TJ, Singh A, Bradley RM, Kellaris PA, Brady RO, Dretchen KL (1997) Therapeutic use of butyrylcholinesterase for cocaine intoxication. Toxicol Appl Pharmacol 145: 372–380

    CAS  PubMed  Google Scholar 

  92. Om A, Ellahham S, Ornato JP, Picone C, Theogaraj J, Corretjer GP, Vetrovec GW (1993) Medical complications of cocaine: Possible relationship to low plasma cholinesterase enzyme. Am Heart J 125: 1114–1117

    CAS  PubMed  Google Scholar 

  93. Ostrea EM Jr, Romero A, Knapp DK, Ostrea AR, Lucena JE, Utarnachitt RB (1994) Postmortem drug analysis of meconium in early-gestation human fetuses exposed to cocaine: Clinical implications. J Pediatr 124: 477–479

    PubMed  Google Scholar 

  94. Jacob P III, Lewis ER, Elias-Baker BA, Jones RT (1990) A pyrolysis product, anhydroecgonine methyl ester (methylecgonidine), is in the urine of cocaine smokers. J Anal Toxicol 14: 353–357

    CAS  PubMed  Google Scholar 

  95. Lobl JK, Carbone LD (1992) Emergency management of cocaine intoxication. Counteracting the effects of today’s ‘favorite drug’. Postgrad Med 91: 161–166

    CAS  PubMed  Google Scholar 

  96. Shanti CM, Lucas CE (2003) Cocaine and the critical care challenge. Crit Care Med 31: 1851–1859

    PubMed  Google Scholar 

  97. Catravas JD, Waters IW, Walz MA, Davis WM (1977) Antidotes for cocaine poisoinign. N Engl J Med 297: 1238

    CAS  PubMed  Google Scholar 

  98. Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD (1989) Cocaine-induced coronary-artery vasoconstriction. N Engl J Med 321: 1557–1562

    CAS  PubMed  Google Scholar 

  99. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD (1990) Potentiation of cocaine-induced coronary vasoconstriction by β-adrenergic blockage. Ann Intern Med 112: 897–903

    CAS  PubMed  Google Scholar 

  100. Pitts WR, Lange RA, Cigarroa JE, Hillis LD (1997) Cocaine-induced myocardial ischemia and infarction: Pathophysiology, recognition, and management. Prog Cardiovasc Dis 40: 65–76

    CAS  PubMed  Google Scholar 

  101. McCord J, Jneid H, Hollander JE, de Lemos JA, Cercek B, Hsue P, Gibler WB, Ohman EM, Drew B, Philippides G, Newby LK (2008) Management of cocaine-associated chest pain and myocardial infarction: A scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. Circulation 117: 1897–1907

    PubMed  Google Scholar 

  102. Williams RG, Kavanagh KM, Teo KK (1996) Pathophysiology and treatment of cocaine toxicity: Implications for the heart and cardiovascular system. Can J Cardiol 12: 1295–1301

    CAS  PubMed  Google Scholar 

  103. Hoffman RS, Smilkstein MJ, Goldfrank LR (1990) Whole bowel irrigation and the cocaine body-packer: A new approach to a common problem. Am J Emerg Med 8: 523–527

    CAS  PubMed  Google Scholar 

  104. Hoffman RS, Chiang WK, Weisman RS, Goldfrank LR (1990) Prospective evaluation of “crackvial” ingestions. Vet Hum Toxicol 32: 164–167

    CAS  PubMed  Google Scholar 

  105. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR (2005) Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 58: 158–164

    CAS  PubMed  Google Scholar 

  106. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, Jack L, Fox B (2002) Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 20: 1196–1204

    CAS  PubMed  Google Scholar 

  107. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, French TL, Thompson TL, Schad VC, Greenstein JL, Gefter ML, Exley MA, Swain PA, Briner TJ (1996) Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2: 1129–1132

    CAS  PubMed  Google Scholar 

  108. Koetzner L, Deng S, Sumpter TL, Weisslitz M, Abner RT, Landry DW, Woods JH (2001) Titer-dependent antagonism of cocaine following active immunization in rhesus monkeys. J Pharmacol Exp Ther 296: 789–796

    CAS  PubMed  Google Scholar 

  109. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ (2007) A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharmacol Exp Ther 320: 145–153

    CAS  PubMed  Google Scholar 

  110. Paula S, Tabet MR, Farr CD, Norman AB, Ball WJ Jr (2004) Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. J Med Chem 47: 133–142

    CAS  PubMed  Google Scholar 

  111. Norman AB, Norman MK, Buessing WR, Tabet MR, Tsibulsky VL, Ball WJ (2009) The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats. J Pharmacol Exp Ther 328: 873–881

    CAS  PubMed  Google Scholar 

  112. Gao D, Narasimhan DL, Macdonald J, Brim R, Ko MC, Landry DW, Woods JH, Sunahara RK, Zhan CG (2009) Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol 75: 318–323

    CAS  PubMed  Google Scholar 

  113. Gao Y, LaFleur D, Shah R, Zhao Q, Singh M, Brimijoin S (2008) An albumin-butyryl-cholinesterase for cocaine toxicity and addiction: Catalytic and pharmacokinetic properties. Chem Biol Interact 175: 83–87

    CAS  PubMed  Google Scholar 

  114. Jutkiewicz EM, Baladi MG, Cooper ZD, Narashimhan D, Sunahara RK, Woods JH (2008) A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med, in press

    Google Scholar 

  115. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G, Zhao K, Briscoe RJ, Almonte R, Woods JH, Landry DW (1998) A catalytic antibody against cocaine prevents cocaine’s reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95: 10176–10181

    CAS  PubMed  Google Scholar 

  116. Zheng F, Zhan CG (2008) Structure-and-mechanism-based design and discovery of therapeutics for cocaine overdose and addiction. Org Biomol Chem 6: 836–843

    CAS  PubMed  Google Scholar 

  117. Patrick KS, Straughn AB, Perkins JS, Gonzalez MA (2009) Evolution of stimulants to treat ADHD: Transdermal methylphenidate. Hum Psychopharmacol 24: 1–17

    CAS  PubMed  Google Scholar 

  118. Sever PS, Caldwell J, Dring LG, Williams RT (1973) The metabolism of amphetamine in dependent subjects. Eur J Clin Pharmacol 6: 177–180

    CAS  PubMed  Google Scholar 

  119. Takekawa K, Ohmori T, Kido A, Oya M (2007) Methamphetamine body packer: Acute poisoning death due to massive leaking of methamphetamine. J Forensic Sci 52: 1219–1222

    CAS  PubMed  Google Scholar 

  120. Molina NM, Jejurikar SG (1999) Toxicological findings in a fatal ingestion of methamphetamine. J Anal Toxicol 23: 67–68

    CAS  PubMed  Google Scholar 

  121. Logan BK, Fligner CL, Haddix T (1998) Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43: 28–34

    CAS  PubMed  Google Scholar 

  122. Lan KC, Lin YF, Yu FC, Lin CS, Chu P (1998) Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 97: 528–533

    CAS  PubMed  Google Scholar 

  123. Chan P, Chen JH, Lee MH, Deng JF (1994) Fatal and nonfatal methamphetamine intoxication in the intensive care unit. J Toxicol Clin Toxicol 32: 147–155

    CAS  PubMed  Google Scholar 

  124. McKetin R, McLaren J, Lubman DI, Hides L (2006) The prevalence of psychotic symptoms among methamphetamine users. Addiction 101: 1473–1478

    PubMed  Google Scholar 

  125. Nixon AL, Long WH, Puopolo PR, Flood JG (1995) Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 41: 955–956

    CAS  PubMed  Google Scholar 

  126. Segal DS, Kuczenski R (1997) An escalating dose “binge” model of amphetamine psychosis: Behavioral and neurochemical characteristics. J Neurosci 17: 2551–2566

    CAS  PubMed  Google Scholar 

  127. Thurman EM, Pedersen MJ, Stout RL, Martin T (1992) Distinguishing sympathomimetic amines from amphetamine and methamphetamine in urine by gas chromatogrphy/mass spectrometry. J Anal Toxicol 16: 19–27

    CAS  PubMed  Google Scholar 

  128. Zimmerman JL (2003) Poisonings and overdoses in the intensive care unit: General and specific management issues. Crit Care Med 31: 2794–2801

    PubMed  Google Scholar 

  129. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW (1999) Methamphetamine abuse and emergency department utilization. West J Med 170: 198–202

    CAS  PubMed  Google Scholar 

  130. Richards JR, Johnson EB, Stark RW, Derlet RW (1999) Methamphetamine abuse and rhabdomyolysis in the ED: A 5-year study. Am J Emerg Med 17: 681–685

    CAS  PubMed  Google Scholar 

  131. Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, Owens SM (2003) Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol 461: 119–128

    CAS  PubMed  Google Scholar 

  132. Gentry WB, Laurenzana EM, Williams DK, West JR, Berg RJ, Terlea T, Owens SM (2006) Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol 6: 968–977

    CAS  PubMed  Google Scholar 

  133. Gentry WB, Rüedi-Bettschen D, Owens SM (2009) Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin 5: 206–213

    CAS  PubMed  Google Scholar 

  134. McMillan DE, Hardwick WC, Li M, Gunnell MG, Carroll FI, Abraham P, Owens SM (2004) Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther 309: 1248–1255

    CAS  PubMed  Google Scholar 

  135. Hutchings DE, Brake SC, Banks AN, Nero TJ, Dick LS, Zmitrovich AC (1991) Prenatal Δ9-tetrahydrocannabinol in the rat: Effects on auditory startle in adulthood. Neurotoxicol Teratol 13: 413–416.

    CAS  PubMed  Google Scholar 

  136. Razdan RK (1986) Structure-activity relationships in cannabinoids. Pharmacol Rev 38: 75–149

    CAS  PubMed  Google Scholar 

  137. Hollister LE (1974) Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of Δ9-tetrahydrocannabinol. Pharmacology 11: 3–11

    CAS  PubMed  Google Scholar 

  138. Lemberger L, McMahon R, Archer R, Matsumoto K, Rowe H (1974) Pharmacologic effects and physiologic disposition of Δ6a, 10a dimethyl heptyl tetrahydrocannabinol (DMHP) in man. Clin Pharmacol Ther 15: 380–386

    CAS  PubMed  Google Scholar 

  139. Perez-Reyes M, Owens SM, Di GS (1981) The clinical pharmacology and dynamics of marihuana cigarette smoking. J Clin Pharmacol 21: 201S–207S

    CAS  PubMed  Google Scholar 

  140. Robson P (2005) Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 719–756

    Google Scholar 

  141. Williamson EM, Evans FJ (2000) Cannabinoids in clinical practice. Drugs 60: 1303–1314

    CAS  PubMed  Google Scholar 

  142. Mechoulam R, Carlini EA (1978) Toward drugs derived from cannabis. Naturwissenschaften 65: 174–179

    CAS  PubMed  Google Scholar 

  143. Bech P, Rafaelsen L, Rafaelsen OJ (1974) Cannabis: A psychopharmacological review. Dan Med Bull 21: 106–120

    CAS  PubMed  Google Scholar 

  144. Thomas R, Chesher G (1973) The pharmacology of marihuana. Med J Aust 2: 229–237

    CAS  PubMed  Google Scholar 

  145. Nahas GG (1986) Cannabis: Toxicological properties and epidemiological aspects. Med J Aust 145: 82–87

    CAS  PubMed  Google Scholar 

  146. Johansson EK, Hollister LE, Halldin MM (1989) Urinary elimination half-life of Δ1-tetrahydrocannabinol-7-oic acid in heavy marijuana users after smoking. NIDA Res Monogr 95: 457–458

    CAS  PubMed  Google Scholar 

  147. Leweke FM, Gerth CW, Klosterkotter J (2004) Cannabis-associated psychosis: Current status of research. CNS Drugs 18: 895–910

    PubMed  Google Scholar 

  148. Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178: 116–122

    CAS  PubMed  Google Scholar 

  149. Marcus AM, Klonoff H, Low M (1974) Psychiatric status of the marihuana user. Can Psychiatr Assoc J 19: 31–39

    CAS  PubMed  Google Scholar 

  150. Hochman JS, Brill NQ (1971) Marijuana intoxication: Pharmacological and psychological factors. Dis Nerv Syst 32: 676–679

    CAS  PubMed  Google Scholar 

  151. Thacore VR, Shukla SR (1976) Cannabis psychosis and paranoid schizophrenia. Arch Gen Psychiatry 33: 383–386

    CAS  PubMed  Google Scholar 

  152. MacInnes DC, Milleer KM (1984) Fatal coronary artery thrombosis associated with cannabis smoking. J R Coll Gen Pract 34: 575–576

    CAS  PubMed  Google Scholar 

  153. Vaziri ND, Thomas R, Sterling M, Seiff K, Pahl MV, Davila J, Wilson A (1981) Toxicity with intravenous injection of crude marijuana extract. Clin Toxicol 18: 353–366

    CAS  PubMed  Google Scholar 

  154. Nihira M, Hayashida M, Ohno Y, Inuzuka S, Yokota H, Yamamoto Y (1998) Urinalysis of body packers in Japan. J Anal Toxicol 22: 61–65

    CAS  PubMed  Google Scholar 

  155. Osterwalder JJ (1995) Patients intoxicated with heroin or heroin mixtures: How long should they be monitored? Eur J Emerg Med 2: 97–101

    CAS  PubMed  Google Scholar 

  156. Voytek B, Berman SM, Hassid BD, Simon SL, Mandelkern MA, Brody AL, Monterosso J, Ling W, London ED (2005) Differences in regional brain metabolism associated with marijuana abuse in methamphetamine abusers. Synapse 57: 113–115

    CAS  PubMed  Google Scholar 

  157. Forney R, Martz R, Lemberger L, Rodda B (1976) The combined effect of marihuana and dextroamphetamine. Ann NY Acad Sci 281: 162–170

    CAS  PubMed  Google Scholar 

  158. Wall ME, Brine DR, Pitt CG, Perez-Reyes M (1972) Identification of Δ9-tetrahydrocannabinol and metabolites in man. J Am Chem Soc 94: 8579–8581

    CAS  PubMed  Google Scholar 

  159. DiGregorio GJ, Sterling GH (1987) Marijuana pharmacology and urine testing. Am Fam Physician 35: 209–212

    CAS  PubMed  Google Scholar 

  160. Huestis MA, Cone EJ (1998) Differentiating new marijuana use from residual drug excretion in occasional marijuana users. J Anal Toxicol 22: 445–454

    CAS  PubMed  Google Scholar 

  161. Cone EJ, Johnson RE (1986) Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther 40: 247–256

    CAS  PubMed  Google Scholar 

  162. Stuyt EB, Sajbel TA, Allen MH (2006) Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. Am J Addict 15: 166–173

    PubMed  Google Scholar 

  163. Berk M, Brook S, Trandafir AI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: A double-blind randomized controlled trial. Int Clin Psychopharmacol 14: 177–180

    CAS  PubMed  Google Scholar 

  164. Baldridge EB, Bessen HA (1990) Phencyclidine. Emerg Med Clin North Am 8: 541–550

    CAS  PubMed  Google Scholar 

  165. Burns RS, Lerner SE (1976) Perspectives: Acute phencyclidine intoxication. Clin Toxicol 9: 477–501

    CAS  PubMed  Google Scholar 

  166. McCarron MM (1986) Phencyclidine intoxication. NIDA Res Monogr 64: 209–217

    CAS  PubMed  Google Scholar 

  167. Morgan JP, Solomon JL (1978) Phencyclidine. Clinical pharmacology and toxicity. NY State J Med 78: 2035–2038

    CAS  Google Scholar 

  168. Bronner W, Nyman P, von Minden D (1990) Detectability of phencyclidine and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in adulterated urine by radioimmunoassay and fluorescence polarization immunoassay. J Anal Toxicol 14: 368–371

    CAS  PubMed  Google Scholar 

  169. Burns RS, Lerner SE (1978) Causes of phencyclidine-related deaths. Clin Toxicol 12: 463–481

    CAS  PubMed  Google Scholar 

  170. Owens SM, Gunnell M, Laurenzana EM, Valentine JL (1993) Dose-and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1. J Pharmacol Exp Ther 265: 1261–1266

    CAS  PubMed  Google Scholar 

  171. Baskin LB, Morgan DL (1997) Drugs detected in patients suspected of acute intoxication. Tex Med 93: 50–58

    CAS  PubMed  Google Scholar 

  172. Fallis RJ, Aniline O, Weiner LP, Pitts FN Jr (1982) Massive phencyclidine intoxication. Arch Neurol 39: 316

    CAS  PubMed  Google Scholar 

  173. McCann DJ, Winter JC (1986) Effects of phencyclidine, N-allyl-N-normetazocine (SKF-10,047), and verapamil on performance in a radial maze. Pharmacol Biochem Behav 24: 187–191

    CAS  PubMed  Google Scholar 

  174. Rappolt RT Sr, Gay GR, Farris RD (1980) Phencyclidine (PCP) intoxication: Diagnosis in stages and algorithms of treatment. Clin Toxicol 16: 509–529

    PubMed  Google Scholar 

  175. Walker S, Yesavage JA, Tinklenberg JR (1981) Acute phencyclidine (PCP) intoxication: Quantitative urine levels and clinical management. Am J Psychiatry 138: 674–675

    CAS  PubMed  Google Scholar 

  176. Barton C H, Sterling ML, Vaziri ND (1980) Rhabdomyolysis and acute renal failure associated with phencyclidine intoxication. Arch Intern Med 140: 568–569

    CAS  PubMed  Google Scholar 

  177. Bessen HA (1982) Intracranial hemorrhage associated with phencyclidine abuse. J Am Med Assoc 248: 585–586

    CAS  Google Scholar 

  178. Brecher M, Wang BW, Wong H, Morgan JP (1988) Phencyclidine and violence: Clinical and legal issues. J Clin Psychopharmacol 8: 397–401

    CAS  PubMed  Google Scholar 

  179. Burns RS, Lerner SE, Corrado R, James SH, Schnoll SH (1975) Phencyclidine — States of acute intoxication and fatalities. West J Med 123: 345–349

    CAS  PubMed  Google Scholar 

  180. Cogen FC, Rigg G, Simmons JL, Domino EF (1978) Phencyclidine-associated acute rhabdomyolysis. Ann Intern Med 88: 210–212

    CAS  PubMed  Google Scholar 

  181. Eastman JW, Cohen SN (1975) Hypertensive crisis and death associated with phencyclidine poisoning. J Am Med Assoc 231: 1270–1271

    CAS  Google Scholar 

  182. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA (1981) Acute phencyclidine intoxication: Clinical patterns, complications, and treatment. Ann Emerg Med 10: 290–297

    CAS  PubMed  Google Scholar 

  183. Stein GY, Fradin Z, Ori Y, Singer P, Korobko Y, Zeidman A (2005) Phencyclidine-induced multiorgan failure. Isr Med Assoc J 7: 535–537

    PubMed  Google Scholar 

  184. Stein JI (1973) Phencyclidine induced psychosis. The need to avoid unnecessary sensory influx. Mil Med 138: 590–591

    CAS  PubMed  Google Scholar 

  185. ElSohly MA, Little TL Jr, Mitchell JM, Paul BD, Mell LD Jr, Irving J (1988) GC/MS analysis of phencyclidine acid metabolite in human urine. J Anal Toxicol 12: 180–182

    CAS  PubMed  Google Scholar 

  186. ElSohly MA, Stanford DF (1990) Cutoff of 25 ng/mL for the EMIT d.a.u. phencyclidine assay. J Anal Toxicol 14: 192–193

    CAS  PubMed  Google Scholar 

  187. McCarron MM, Walberg CB, Soares JR, Gross SJ, Baselt RC (1984) Detection of phencyclidine usage by radioimmunoassay of saliva. J Anal Toxicol 8: 197–201

    CAS  PubMed  Google Scholar 

  188. Walberg CB, McCarron MM, Schulze BN (1983) Quantitation of phencyclidine in serum by enzyme immunoassay: Results in 405 patients. J Anal Toxicol 7: 106–110

    CAS  PubMed  Google Scholar 

  189. Grover D, Yeragani VK, Keshavan MS (1986) Improvement of phencyclidine-associated psychosis with ECT. J Clin Psychiatry 47: 477–478

    CAS  PubMed  Google Scholar 

  190. Lahmeyer HW, Stock PG (1983) Phencyclidine intoxication, physical restraint, and acute renal failure: Case report. J Clin Psychiatry 44: 184–185

    CAS  PubMed  Google Scholar 

  191. Rappolt RT, Gay GR, Farris RD (1979) Emergency management of acute phencyclidine intoxication. J Am Coll Emerg Physicians-JACEP 8: 68–76

    CAS  Google Scholar 

  192. Hardin JS, Wessinger WD, Wenger GR, Proksch JW, Laurenzana EM, Owens SM (2002) A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J Pharmacol Exp Ther 302: 119–126

    CAS  PubMed  Google Scholar 

  193. Laurenzana EM, Gunnell MG, Gentry WB, Owens SM (2003) Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody. J Pharmacol Exp Ther 306: 1092–1098

    CAS  PubMed  Google Scholar 

  194. Proksch JW, Gentry WB, Owens SM (2000) The effect of rate of drug administration on the extent and time course of phencyclidine distribution in rat brain, testis, and serum. Drug Metab Dispos 28: 742–747

    CAS  PubMed  Google Scholar 

  195. Valentine JL, Arnold LW, Owens SM (1994) Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 269: 1079–1085

    CAS  PubMed  Google Scholar 

  196. Valentine JL, Mayersohn M, Wessinger WD, Arnold LW, Owens SM (1996) Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J Pharmacol Exp Ther 278: 709–716

    CAS  PubMed  Google Scholar 

  197. Valentine JL, Owens SM (1996) Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278: 717–724

    CAS  PubMed  Google Scholar 

  198. Pitas G, Laurenzana EM, Williams DK, Owens SM, Gentry WB (2006) Anti-phencyclidine monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos 34: 906–912

    CAS  PubMed  Google Scholar 

  199. Proksch JW, Gentry WB, Owens, SM (2000) Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats. J Pharmacol Exp Ther 292: 831–837

    CAS  PubMed  Google Scholar 

  200. Lacy HM, Gunnell MG, Laurenzana EM, Owens, SM (2008) Engineering and characterization of a mouse/human chimeric anti-phencyclidine monoclonal antibody. Int Immunopharmacol 8: 1–11

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), 6001 Executive Boulevard, Bethesda, MD, 20892, USA

    Ivan D. Montoya & David J. McCann

Authors
  1. Ivan D. Montoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David J. McCann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Federal Institute for Risk Assessment, Thielallee 88-92, 14195, Berlin, Germany

    Andreas Luch

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Birkhäuser Verlag/Switzerland

About this chapter

Cite this chapter

Montoya, I.D., McCann, D.J. (2010). Drugs of abuse: management of intoxication and antidotes. In: Luch, A. (eds) Molecular, Clinical and Environmental Toxicology. Experientia Supplementum, vol 100. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8338-1_15

Download citation

Publish with us

Policies and ethics

Search

Navigation